VANCOUVER, Oct. 7 /PRNewswire/ -- Neuromed Technologies Inc., a biopharmaceutical company developing the next generation of chronic pain drugs, today announced it has appointed Mark Corrigan, M.D., to its Board of Directors.
“Dr. Corrigan is a clinical expert who has been a key figure in bringing several important drugs to the market,” said Darrell Elliott, Managing Director at MDS Capital and Chairman of Neuromed’s Board of Directors. “He recognizes the potential of Neuromed’s compounds and his extensive pharmaceutical experience in clinical research, drug development and regulatory affairs will be invaluable to the company.”
Dr. Corrigan is Executive Vice President of Research and Development at Sepracor Inc., a U.S.-based specialty pharmaceutical company. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, most recently as Group Vice President of Global Clinical Research and Experimental Medicine. Before joining the pharmaceutical industry, Dr. Corrigan also spent seven years in academic research at the University of North Carolina Medical School, focusing on psychoneuroendocrinology. Dr. Corrigan has been involved in the development of several drugs including Estorra(TM) for the treatment of insomnia, Xopenex(R) for the treatment of bronchospasm, such as asthma, Mirapex for the treatment of Parkinson’s disease, Delavirdine for AIDS, Cycloprovera for birth control, Xalatan for glaucoma, Camptosar for colorectal cancer and Reboxetine for depression.
“Dr. Corrigan is a proven leader and has an excellent track record in pharmaceutical drug development,” said Dr. Christopher Gallen, President & CEO. “He brings with him clinical development expertise as well as extensive knowledge of the development of drugs for nervous system disorders, which will further strengthen Neuromed. We are delighted to have him join our Board.”
About Neuromed
Neuromed is a private biopharmaceutical company committed to developing the next generation of chronic pain drugs. It is the only company in the world with a sole focus on target-specific calcium channel drugs. Located in Vancouver, BC, and Philadelphia, PA, the company’s drug development programs are designed around validated clinical targets associated with large unmet markets including pain, anxiety, epilepsy and cardiovascular diseases. Website: http://www.neuromedtech.com/
Corporate Communications Contact: Julie Jang Manager, Communications & Human Resources Phone: (604) 822-9970 Email: jjang@neuromedtech.com
NeuroMed Technologies Inc.
CONTACT: Corporate Communications Contact: Julie Jang, Manager,Communications & Human Resources, Phone: (604) 822-9970, Email:jjang@neuromedtech.com
